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Introduction
Numerous studies have identified regional differences in the brain structure of psychiatric patients and described both transdiagnostic and disorder-specific processes of gray matter (GM) reduction in patients (1) (2) (3) (4) (5) (6) (7) (8) (9) . However, the biological mechanisms contributing to such clinically relevant regional GM differences are mostly unclear. One possibility is that GM loss occurs as a consequence of disease manifestation. Alternatively, as a genetic influence on cortical and subcortical brain regions is well documented (10) (11) (12) (13) (14) (15) (16) , GM changes may precede the onset of psychopathology and directly increase disease risk. A third explanation is that reduced GM volume in patients constitutes a regional vulnerability. In this model, the susceptibility to develop psychiatric symptoms would increase if genetic risk factors and unfavorable environmental factors or aging processes jointly affect specific brain regions. In a large meta-analysis of 193 imaging studies, Goodkind and colleagues found that GM volumes obtained from structural magnetic resonance imaging (MRI) using voxel-based morphometry (VBM) were reduced across six psychiatric diagnoses in parts of the bilateral anterior insular cortex (AIC) and the dorsal anterior cingulate cortex (dACC) (1) . Structural and functional connectivity analyses supported that these regions are tightly connected and represent hubs of the salience network (1) . Functional differences in salience processing in these brain regions are associated with diagnostic status and progression of psychiatric disorders (17) . The authors hypothesized that the regions jointly form a common neurobiological substrate (CS) of major psychiatric disorders (1) .
Many studies analyzed genetic risk factors for major psychiatric disorders like schizophrenia, bipolar disorder (BD), and major depressive disorder (MDD). These disorders show substantial heritability (18) and are genetically correlated with each other (19) . Genome-wide association studies (GWAS) identified single-nucleotide polymorphisms (SNPs) contributing risk for several psychiatric disorders, suggesting pleiotropy and partially overlapping etiologies (20, 21) . While some studies reported partial overlaps between brain volumeassociated and disease-associated SNPs, others did not (2, 10, (22) (23) (24) .
The present study aimed to identify genetic variants influencing the CS in the general population. To this end, a combined VBM measure of the three CS regions (hereafter referred to as the first principal component of the CS, CCS), was computed in five population-based cohorts. Meta-analyses of GWAS conducted in these cohorts identified a novel locus significantly associated with the CCS. In secondary analyses, genetic relationships between the CCS and risk for psychiatric disorders were characterized in detail, emphasizing a potentially modulating role of age on the CCS.
Methods and Materials

Sample description
For the GWAS, n=3,136 individuals from five population-based cohorts were investigated. Four cohorts were used in the discovery (1000BRAINS(25), n=539; CONNECT100 (26), n=93; BiDirect (27), n=589; SHIP-2 (28), n=1,050; pooled n=2,271) and the second-largest cohort available in the replication stage (SHIP-Trend (28), n=865). For follow-up analyses, two MDD cohorts with 967 cases and 508 controls were used, BiDirect (29) (n=582 MDD cases; n=311 controls) and MPIP (30, 31) (n=385 MDD cases; n=197 controls). Basic demographic characteristics of the cohorts are described in Tables S1 and S2. The studies were approved by the local ethics committees; all participants provided written informed consent.
VBM preprocessing and extraction of regional and total GM volumes VBM preprocessing (32, 33) was applied to high-resolution T1-weighted images from all participants to create GM maps with non-linear only (NLO) Jacobian modulation. Three spatially disjunct regional GM volumes, based on binarized versions of the joint result areas from the study by Goodkind et al. (1) , and total GM volume were extracted. All GM volumes were corrected for age, age×age, and sex in multiple linear regression models. Handedness was used as an additional covariate for 1000BRAINS, CONNECT100, and BiDirect, and coil type for the MPIP sample. Residuals of these regional volume regression models were combined using principal component analysis (PCA) to create a single measure referred to as the Component of the Common Substrate (CCS; Fig. 1 ).
Genotyping, quality control, and imputation
DNA extraction and genome-wide genotyping were conducted as described before (31, (34) (35) (36) . Genotyping was carried out on different Illumina and Affymetrix microarrays (see the Supplemental Methods and Table S3 ). Quality control (QC) and imputation were conducted separately for each genotyping batch, using the same protocols, in PLINK (37), R, and XWAS (38) ; genotype data were imputed to the 1000 Genomes phase 1 reference panel using SHAPEIT and IMPUTE2 (39) (40) (41) , as described in the Supplement and previously (42) . The population substructure of all five cohorts is shown in Fig. S1 .
Heritability estimation and GWAS
The SNP-based heritability of the CCS was estimated using GCTA on a combined sample of the imputed data from all five cohorts (43, 44 ) (see the Supplemental Methods). GWAS was conducted separately per cohort using PLINK with ancestry components as covariates.
Variants on the X chromosome were analyzed separately by sex, followed by p value-based metaanalysis to allow for different effect sizes per sex. A two-stage design was implemented for the GWAS, using four cohorts as the discovery sample and SHIP-Trend as an independent replication sample. Cohorts were combined by fixed-effects meta-analysis using METAL (45) . There was no indication for genomic inflation of the GWAS test statistics in the single cohorts or the meta-analysis (λ1000=1.01, see Table S4 and Fig. S2 ). Linkage disequilibrium (LD) was analyzed using the 1000 Genomes CEU population in LDmatrix (46) . We carried the two SNPs forward to the replication stage that showed the most robust genome-wide support (p<5×10 -8 ) for an association in the discovery stage and were partially independent of each other (LD r 2 <0.5 with more strongly associated variants). Here, a one-sided p-value <α=0.05/2 (correcting for two LD-independent variants) was considered as successful replication. See the Supplement for additional details.
Gene-set analyses
Gene-set analyses were conducted on the meta-analysis of the discovery-and replication-stage GWAS, using 674 REACTOME gene sets containing 10-200 genes curated from MsigDB 6.2 (47) . Only SNPs within gene boundaries were mapped to RefSeq genes (0 bp window). Analyses were conducted in MAGMA v1.07 using both mean-and top-SNP gene models (48) and in MAGENTA v2 using a top-SNP approach (49) . Here, false discovery rates were calculated to correct for multiple testing.
Comparison to published GWAS of psychiatric disorders
For genome-wide comparisons between our GWAS meta-analysis and published GWAS of psychiatric disorders, summary statistics from the following PGC GWAS were used: cross-disorder 2013 (50), BD 2019 (51), MDD 2018 (with 23andMe) (52) , and schizophrenia 2014 (53) . For additional comparisons, the following GWAS were used: IFGC behavioral frontotemporal dementia (bvFTD) 2014 (54), longevity 85/90 2014 (55) , and three different GWAS from 2017 on epigenetic accelerated aging (EAA) (56) : EAA in all examined brain regions, EAA in prefrontal cortex (PC), and neuronal proportion in PC.
Polygenic risk scores (PRS) were calculated and analyzed in R using imputed genetic data (57) . We ran LD score regression (LDSC) comparing the genetic correlation of published GWAS to the CCS GWAS summary statistics with standard settings (58, 59) . We analyzed whether the order of SNPs ranked by their association strength was random between studies using rank-rank hypergeometric overlap (RRHO) tests (60) . For this analysis, variants were LDpruned in the 1000 Genomes phase 3 EUR subset (61) . Binomial sign tests were conducted in R (binom.test) to analyze whether SNPs associated with the CCS at either p<0.05 or p<1×10 -5 showed the opposite direction of effects in other GWAS more often than expected by chance. For additional details, see the Supplemental Methods.
Figure 1: Generation of the CCS and GWAS analysis workflow. A-B:
Comparison between the CCS and the three individual volumes (A) and the residuals of the three volumes after correction for covariates (B). AIC = anterior insula cortex; dACC = dorsal anterior cingulate cortex C: Histograms of the three extracted volumes and the CCS. Note that A-C show combined data from all five GWAS cohorts. Correlations were left and right AIC: r=0.65, left AIC and dACC: r=0.52, right AIC and dACC: r=0.46. D: GWAS analysis workflow. All measures were extracted using NLObased Jacobian modulation. All GM volumes were corrected for age, age 2 , and sex as covariates; handedness was used as an additional covariate for the three samples 1000BRAINS, CONNECT100, and BiDirect. PCA = principal component analysis; LD = linkage disequilibrium.
Results
Heritability of the imaging CCS
After correction for covariates, the CCS showed a SNP heritability estimate of h 2 g=0.50 (standard error, SE=0.18; p-value=0.0033).
GWAS of the CCS
In the discovery-stage GWAS, twelve SNPs on chromosome 5q35.2 showed genome-wide significant associations with the CCS (p<5×10 -8 ; Fig. 2A and Table S5 ). Most of these SNPs were highly correlated with each other (Table  S6 ). The two partially LD-independent SNPs (pairwise LD r 2 =0.267 in CEU samples) with the most robust support for an association were analyzed further. Of these, variant rs17076061 was significantly associated in the replication cohort (discovery: p=1.51×10 -8 ; replication: one-sided p=9.91×10 -3 ) and also the top-associated variant in the genome-wide meta-analysis of discovery and replication samples (p=1.46×10 -9 ; Table 1 , Fig. 2B -D; Table S5 and Fig. S2-S4 ). This SNP was associated at genome-wide significance only for the CCS but not when examining either whole-brain GM volume or the three GM regions forming the CS separately ( Table  1 ). The minor allele T of SNP rs17076061 (frequency = 0.36) is thus associated with smaller CS volumes. reached genome-wide significance in the discovery GWAS. The two variants rs17076061 and rs72088023 (r 2 =0.267) showed the strongest support for an association in their respective LD blocks and were analyzed in the replication stage. All other variants had pairwise LD>0.5 with either of these two variants, their association strengths are provided for comparison only. pDisc.: discovery stage GWAS p-value; pRepl. (1s): one-sided p-value in the replication cohort; Mbp: mega base pair. C: Regional association plot of the top-associated locus after pooled analysis of the discovery stage GWAS and the replication sample. The color of dots indicates LD with the lead variant (rs17076061; pink). Gray dots represent signals with missing LD r 2 values. cM: centimorgan. D: Forest plot of the pooled analysis of the replicated variant rs17076061 in discovery and replication cohorts. D. P.: pooled analysis of discovery stage cohorts; Repl.: replication; Pool.: pooled analysis of the discovery GWAS and the replication cohort SHIP-Trend. 
Gene-set analyses
In two separate gene-set analyses using GWAS meta-analysis results, the topassociated pathway, significant after correction for multiple testing, was "SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion" (Tables S7-S8 , https://www.reactome.org/content/detail/ R-HSA-399955).
Comparisons of the CCS and the CCS genetic architecture with psychiatric disorders
To characterize the relationship between the CCS and risk for psychiatric disorders, we tested whether results from our CCS GWAS overlapped with results from four published GWAS of psychiatric disorders (PGC cross-disorder (50), BD (51), MDD (52) , and schizophrenia (53)). SNP rs17076061 was not significantly associated with disorders in any of these GWAS (p>0.26, Table S9 ). We ran four separate systematic comparisons with the psychiatric GWAS, following a published workflow (22): First, we calculated PRS using the four GWAS as training data and analyzed associations of these PRS with the CCS. Although the cross-disorder PRS showed a nominally significant association with a smaller CCS at a single PRS threshold (one-sided p=0.01), none of the PRS were significantly associated after correction for multiple testing ( Table 2 ; Table S10 and Fig. S5 ). We also calculated a CCS PRS in an independent MDD case/control sample (MPIP). However, the CSS PRS was not significantly higher in MDD cases at any threshold (one-sided p≥0.55, Table S11 ). Second, no significant genetic correlation was found between the CCS GWAS and any of the psychiatric GWAS using LDSC ( Table 2, Table S12 ). Third, no significant overlap of SNPs ranked by association strength was found with RRHO tests (Table 2; Table S13 , and Fig. S6 ). Fourth, we carried out binomial sign tests and found that CCS-associated variants did not show the opposite effect direction in the psychiatric disorder GWAS more often than expected by chance ( Table 2 and Table S14 ). For detailed results see Tables S10-S13. Details on the four training GWAS datasets are provided in the Methods section. PRS: Association of polygenic risk scores with the CCS; pT = training GWAS data p-value threshold; effect size = linear regression effect size at the pT showing the strongest support for an association (see Table S10 for results of all ten thresholds); p-value: one-sided p-value not corrected for multiple testing. The significance level adjusted for multiple testing was α=0.05/(10×4) =0.00125. LDSC: LD score regression using genome-wide summary statistics; rg = genetic correlation. RRHO: Rank-rank hypergeometric overlap test showing the relative overlap of genome-wide summary statistics. Sign tests: One-sided binomial sign tests for CCS GWAS p-value thresholds p<0.05 and p<1×10 -5 and the corresponding probability of success.
Polygenic risk scores (PRS) Training GWAS Effect size p-value pT
Analyses of age-dependent effects
We confirmed in two MDD case/control cohorts that the CSS was reduced in cases (p=3×10 -6 , Fig. 3A , Table S15 ). We did not observe a significant age-bydiagnosis interaction in this analysis (p=0.07). However, when including such an interaction term, the main effect of MDD diagnosis did not remain significant either (p=0.10, Fig. 3B; Fig. S7 , and Table  S15 ). To test for a non-linear age dependency, we stratified the cohorts into four age groups (see Fig. 3C ). Effect sizes differed between age groups but without showing significant heterogeneity in a meta-analysis across the groups (Q=3.55, p=0.31; Fig. 3C , Table S16 ). The association of the CCS with MDD may thus, potentially, be age-dependent.
When adding an age-by-SNP interaction term to the GWAS model, this term was not significant in the metaanalysis of all five cohorts (p=0.96, Fig.  S8 , and Table S17) but the main effect of variant rs17076061 also did not remain significant (p=0.27, compared to p=1.46×10 -9 without the interaction in the model). When we stratified the analysis by age groups, the effect size varied, yet without significant heterogeneity (Q=2.25, p=0.69; Fig. 3D , Table S16 ).
We investigated whether the global brain volume correction intrinsically contained in NLO Jacobian modulation may have caused these effects. However, results were highly similar when using full Jacobian modulation with total intracranial volume added as a covariate to the regression model for explicit correction of global volume (Supplemental Methods and Table S17 ).
Comparison of the genetic architecture of the CCS and aging-related traits
Due to a potential effect of aging on the CCS, we compared our CCS GWAS with GWAS for EAA (56) and longevity (55) . Furthermore, since the CS regions are central to the salience network, we also analyzed the overlap with GWAS results for bvFTD (54) . SNP rs17076061 did not show a significant association in any of these GWAS (Table S9 ). No significant genetic overlap with any of these GWAS was found after correction for multiple testing, using PRS analyses, LDSC, RRHO, or sign tests (Figs. S5 and S9 and Tables S10 and S12-S14). However, here we observed several nominally significant associations and genetic overlaps, indicating that a weak genetic relationship between the CCS and aging-associated traits might exist.
Figure 3: MDD-specific and age-dependent analyses of the CCS.
A: MDD cases had a significantly smaller CSS in two MDD cohorts (pooled p=3×10 -6 ). B: When a diagnosis-by-age interaction term was added to the regression model, the association of MDD diagnosis with CCS was not significant anymore; the interaction term was also not significant. C: Association of diagnosis with CCS across four age groups (combined sample of both MDD cohorts, the cohort was a covariate in the regression models). D: Association of SNP rs17076061 with CCS across five age groups (combined sample of all five GWAS cohorts, the cohort was a covariate).
Discussion
The CCS is a volumetric MRI-based marker associated with several psychiatric disorders (1) . We conducted a GWAS and follow-up analyses to characterize genetic factors influencing the CCS and their relationship to psychiatric disorders. These analyses produced three main findings: First, the minor allele T of the intergenic variant rs17076061 was associated with a decreased CCS at genome-wide significance and replicated. The SNP locates in between two predicted, uncharacterized long intergenic noncoding RNAs (lincRNA). The closest protein-coding genes to this SNP are "biorientation of chromosomes in cell division 1" (BOD1) and "stanniocalcin 2" (STC2), 75 kbp downstream and 202 kbp upstream of SNP rs17076061, respectively. BOD1 is a regulator of protein phosphatase 2A during cell division and, post-mitotically, a modulator of neuronal function (62): During the cell cycle, BOD1mutant cells showed an accelerated progression through mitosis. BOD1 localized to presynapses in murine neurons and, in Drosophila, neuronspecific knockdown of BOD1 using RNAi caused non-associative learning deficits and abnormal morphology of neuromuscular junctions. Furthermore, alterations at the BOD1 locus might be associated with psychiatric disorders (62, 63) : A mutation in BOD1 co-segregated with intellectual disability in a consanguineous family and somatic deletions in BOD1 have been identified in neuronal samples from a schizophrenia patient, including tissue from the prefrontal cortex. STC2 is a secreted glycoprotein with a possible auto-or paracrine function. In the regulation of apoptosis, the unfolded protein response promotes the expression of potentially neuroprotective STC2 in neuronal cells (64) (65) (66) . Its homolog STC1, a regulator of neuronal, intracellular calcium homeostasis, has been suggested as a biomarker for neurodegenerative disorders (67) . SNP rs17076061 is part of a significant expression quantitative trait locus with STC2 in the pancreas (p=2.2×10 -6 ; GTEx v7 (68)). For the CS regions, the most relevant result from GTEx was for the anterior cingulate cortex (BA24, p=0.03) . This finding was not significant after correction for multiple testing, yet the sample size for this tissue was about half the one for pancreas. SNP rs17076061 likely affects the alternative binding of two transcription factors: the CCS-associated minor allele T supports the binding of E2F, the major allele supports binding of EBF. Moreover, rs17076061 is located within an element that is evolutionarily constrained in mammals (69) . In summary, the associated locus 5q35.2 harbors two protein-coding genes expressed in the brain with either psychiatric or neuroprotective functions.
Second, the neurodevelopmental pathway "SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion" was significantly associated with the CCS. Semaphorin-3A (SEMA3A) is a chemorepellent mediating axon guidance and a chemoattractant for dendrite growth, and plexins are the signaltransducing subunits of the SEMA3A receptor. The pathway is important during neuronal regeneration after brain trauma (70) and SEMA3A and its receptor are associated with impaired tissue regeneration in chronic white matter multiple sclerosis lesions (71) . Both Semaphorin-3A and Plexin A2 are relevant for different psychiatric disorders (72) (73) (74) (75) , supporting a broader, transdiagnostic function of the pathway: SEMA3A may contribute to neurodegeneration in Alzheimer's disease (73) . It is upregulated in the brain of schizophrenia patients and has been suggested to contribute to the synaptic pathology of the disorder (72) . Plexin A2 (PLXNA2), one of the 13 gene-set members, is associated with schizophrenia, anxiety, and depression (74, 75) and is relevant for associate learning; Plxna2-deficient mice showed impaired neurogenesis and altered synaptic morphology (76) . Of note, the SEMA3A homolog SEMA5A has been implicated in autism and intellectual diability (77, 78) .
Third, we did not find evidence for a systematic overlap between the genetic architecture of the CCS and major psychiatric disorders. Neither was the topassociated variant rs17076061 directly associated with risk for psychiatric disorders in any of the examined GWAS nor were CCS PRS significantly higher in MDD cases. Moreover, PRS for psychiatric disorders were not significantly associated with the CCS after correction for multiple testing. However, the PRS for cross-disorder psychiatric risk was positively correlated with the CCS at nominal significance. This lack of a genetic overlap with psychiatric disorders might seem contradictory at first sight, but this finding is in line with previous studies that found either no or only a weak, nominally significant genetic correlation between either subcortical volumes and schizophrenia or hippocampal volume and MDD, respectively (22, 23) . A metaanalysis of genetic factors influencing subcortical volumes with 40,000 individuals identified a significant genetic correlation between BD and the nucleus accumbens and the caudate nucleus, but no such correlation for schizophrenia (10) . Interestingly, a recent study described an age-dependent association of schizophrenia PRS with cortical thickness of the salience network, a similar brain phenotype (79) . Importantly, the analysis of a genetic overlap, as conducted by us and others (22, 23) , investigated genome-wide similarities between GWAS. If only some variants showed a joint association or different loci exhibited mixed effect directions, the methods used here could be failing to detect similarities.
Several explanations are compatible with the finding that individuals at high polygenic risk for disease did not show a significantly reduced CCS. First, genetic factors shaping the CCS might contribute to disease risk without exhibiting strong univariate, additive effects, as tested for in our GWAS. This explanation is plausible because both the CCS variance explained by diagnostic status (R 2 =1.9% in BiDirect and 3.7% in MPIP) and by rs17076061 (R 2 =1.2%, sample sizeweighted mean across cohorts) were small. Thus, any direct correlation between the SNP and MDD or other diagnoses would be expected to be low. Second, the CS regions might constitute a vulnerable brain network for psychiatric disorders. In this case, CCS-associated variants could increase the risk for GM loss in these regions, likely in interaction with other risk constellations, e.g., age or prolonged psychosocial stress. Thereby, smaller CS volumes might lead to brain dysfunction in susceptible individuals and specifically influence clinical presentations, e.g., cognitive functions. Interestingly, the CS regions represent nodes of the salience network, and CCSassociated SNPs might indirectly influence the structural integrity of this network, leading to deficits in achieving flexible cognitive control (80) . The model in which CS regions represent regional vulnerability is supported by our observation of a possible non-linear influence of age on the association of the CCS with MDD. Non-linear aging trajectories of volumetric measures are a known phenomenon, e.g., for subcortical brain structures (81, 82) . Importantly, the studies analyzed in Goodkind et al. (1) assumed a common aging model between MDD cases and controls. Hence, latent group-by-age effects may have influenced their result, and their proposed neurobiological substrate could contain effects of accelerated aging in psychiatric patients (7) . This might explain why the association of rs17076061 with the CCS varied by age, despite correction of the GM volumes for age effects.
The CS brain regions could thus be subject to accelerated brain aging in psychiatric patients, and rs17076061 could increase the risk for this phenomenon. Such an interaction between age and disorder is conceivable since we detected no genetic overlap between CCS-associated SNPs and genetic factors influencing EAA or longevity. Interestingly, the salience network is critically involved in accelerated cognitive decline during aging (83) . Cognitive correlates of the CS have also been demonstrated in the original study by Goodkind et al. (1) . Although the salience network is specifically prone to degeneration in bvFTD (84, 85) , no overlap between CCS-and bvFTD-associated genetic variants was found. This observation once more suggests that a translation of the rs17076061 effects into an accelerated aging phenotype either occurs in interaction with other genetic risk factors or in the context of established psychiatric disease.
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